翰森制药签署独家许可协议 将获1.12亿美元首付款
财中社12月18日电翰森制药（03692）发布公告，宣布其全资附属公司上海翰森生物医药科技有限公司及江苏豪森药业集团有限公司与默沙东的一间全资附属公司签订全球独家许可协议。根据该协议，许可人将授予被许可人开发、生产及商业化临床前口服小分子GLP-1受体激动剂HS-10535的全球独家许可。许可人将获得1.12亿美元的首付款，并有资格根据该产品的开发、注册审批和商业化进展收取最高19亿美元的里程碑付款，以及基于产品销售的特许权使用费。
董事会认为，该许可协议的签订符合公司的整体最佳利益，并将最大限度地发挥集团技术平台的科学及商业价值。根据公告，被许可人与其最终实益拥有者均独立于公司及其关联人士，且与公司并无关联。此次交易属于公司的日常及一般业务过程中的收益性质交易，不构成任何须予公布的交易或关联交易。
（文章来源：财中社）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10